AKEBIA THERAPEUTICS, INC. (AKBA) Spending and interest coverage
- R&D / revenue · 12 months: Value 32.16%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 6.08%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 32.16% | Research and development expense / revenue. Period ending 2026-06-30. $70.46M ÷ $219.06M × 100 ≈ 32.16% |
| Stock-based compensation / revenue · 12 months | 6.08% | Share-based compensation / revenue. Period ending 2026-06-30. $13.31M ÷ $219.06M × 100 ≈ 6.08% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 70.46M USD | Research and Development Expense |
| Revenue | 219.06M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 13.31M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -15.13M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $70.46M | $219.06M | $13.31M | $-15.13M | (m) | 32.16% | 6.08% | (m) | (m) |
| 2026-03-31 | $67.41M | $232.40M | $12.76M | $5.29M | (m) | 29.01% | 5.49% | (m) | (m) |
| 2025-12-31 | $62.36M | $236.20M | $11.28M | $23.50M | (m) | 26.40% | 4.78% | (m) | (m) |
| 2025-09-30 | $47.50M | $225.07M | $9.78M | $17.75M | (m) | 21.10% | 4.35% | (m) | (m) |
| 2025-06-30 | $41.04M | $203.73M | $8.21M | $791.00K | (m) | 20.14% | 4.03% | (m) | (m) |
| 2025-03-31 | $37.67M | $184.91M | $7.60M | $-22.02M | (m) | 20.37% | 4.11% | (m) | (m) |
| 2024-12-31 | $37.65M | $160.18M | $7.78M | $-50.47M | (m) | 23.51% | 4.85% | (m) | (m) |
| 2024-09-30 | $35.73M | $169.88M | $7.59M | $-34.79M | (m) | 21.03% | 4.47% | (m) | (m) |
| 2024-06-30 | $40.58M | $174.50M | $7.77M | $-35.32M | (m) | 23.25% | 4.45% | (m) | (m) |
| 2024-03-31 | $53.12M | $187.22M | $9.19M | $-35.59M | (m) | 28.37% | 4.91% | (m) | (m) |
| 2023-12-31 | $63.08M | $194.62M | $9.32M | $-46.26M | (m) | 32.41% | 4.79% | (m) | (m) |
| 2023-09-30 | $85.31M | $194.21M | $10.84M | $-52.50M | (m) | 43.93% | 5.58% | (m) | (m) |
| 2023-06-30 | $100.01M | $200.88M | $12.38M | $-89.87M | (m) | 49.79% | 6.16% | (m) | (m) |
| 2023-03-31 | $104.97M | $271.03M | $15.80M | $-45.56M | (m) | 38.73% | 5.83% | (m) | (m) |
| 2022-12-31 | $129.11M | $292.60M | $17.85M | $-79.11M | (m) | 44.13% | 6.10% | (m) | (m) |
| 2022-09-30 | $126.77M | $297.03M | $19.44M | $-138.92M | (m) | 42.68% | 6.55% | (m) | (m) |
| 2022-06-30 | $139.89M | $296.82M | $21.68M | $-145.63M | (m) | 47.13% | 7.30% | (m) | (m) |
| 2022-03-31 | $151.07M | $222.97M | $21.28M | $-258.88M | (m) | 67.75% | 9.54% | (m) | (m) |
| 2021-12-31 | $147.85M | $213.58M | $22.73M | $-265.32M | (m) | 69.23% | 10.64% | (m) | (m) |
| 2021-09-30 | $155.87M | $210.67M | $24.19M | $-284.57M | (m) | 73.99% | 11.48% | (m) | (m) |
| 2021-06-30 | $162.26M | $221.90M | $25.19M | $-287.77M | (m) | 73.12% | 11.35% | (m) | (m) |
| 2021-03-31 | $177.87M | $259.13M | $25.54M | $-382.25M | (m) | 68.64% | 9.85% | (m) | (m) |
| 2020-12-31 | $218.49M | $295.31M | $24.46M | $-376.44M | (m) | 73.99% | 8.28% | (m) | (m) |
| 2020-09-30 | $261.32M | $308.16M | $23.31M | $-385.93M | (m) | 84.80% | 7.56% | (m) | (m) |
| 2020-06-30 | $288.97M | $340.15M | $19.33M | $-383.74M | (m) | 84.95% | 5.68% | (m) | (m) |
| 2020-03-31 | $321.85M | $350.81M | $14.75M | $-269.44M | (m) | 91.74% | 4.20% | (m) | (m) |
| 2019-12-31 | $322.97M | $335.00M | $11.93M | $-286.29M | (m) | 96.41% | 3.56% | (m) | (m) |
| 2019-09-30 | $329.61M | $325.30M | $19.05M | $-281.56M | (m) | 101.33% | 5.86% | (m) | (m) |
| 2019-06-30 | $325.73M | $286.49M | $18.69M | $-253.49M | (m) | 113.70% | 6.52% | (m) | (m) |
| 2019-03-31 | $311.95M | $234.48M | $18.90M | $-229.63M | (m) | 133.04% | 8.06% | (m) | (m) |
| 2018-12-31 | $291.01M | $207.74M | $19.04M | $-178.16M | (m) | 140.08% | 9.17% | (m) | (m) |
| 2018-09-30 | $272.34M | (m) | $9.17M | $-76.64M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $260.41M | (m) | $9.07M | $-72.97M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $232.25M | (m) | $9.08M | $-59.44M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $230.89M | (m) | $8.87M | $-79.92M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $195.95M | (m) | (m) | $-129.33M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $168.47M | (m) | (m) | $-141.33M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $155.60M | (m) | (m) | $-155.39M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $115.78M | (m) | $5.83M | $-136.46M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $96.59M | $0.00 | (m) | $-118.47M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $80.96M | $0.00 | (m) | $-101.96M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $56.59M | $0.00 | (m) | $-76.66M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $43.02M | $0.00 | (m) | $-61.51M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $37.55M | $0.00 | (m) | $-52.07M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $28.40M | (m) | (m) | $-41.98M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $26.75M | (m) | (m) | $-38.93M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $25.40M | $0.00 | (m) | $-37.94M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $10.78M | (m) | (m) | $-15.93M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $5.63M | (m) | (m) | $-8.52M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |